Skip to main content
151 search results for:

Carboplatin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 17-09-2021 | ESMO 2021 | Conference coverage | Article

    BrighTNess update confirms benefit of adding carboplatin to neoadjuvant chemo in TNBC

    Adding carboplatin to neoadjuvant paclitaxel is sufficient to boost the outcomes of patients with triple-negative breast cancer, with no further improvement from the addition of veliparib to the dual regimen, confirms a follow-up analysis of the BrighTNess trial.

  2. 10-05-2021 | ESMO Breast 2021 | Conference coverage | Article

    GELATO: Atezolizumab–carboplatin promising for metastatic lobular breast cancer

    Early results from the GELATO trial point to the potential of atezolizumab plus carboplatin for the treatment of metastatic invasive lobular breast cancer.

  3. 04-02-2021 | Mesothelioma | News | Article
    WCLC 2020

    Real-world data support carboplatin use in malignant pleural mesothelioma

    Among people receiving first-line platinum-based chemotherapy for malignant pleural mesothelioma, carboplatin is associated with similar overall survival as cisplatin, show findings presented at the IASLC 2020 World Conference on Lung Cancer.

  4. 27-08-2020 | Breast cancer | News | Article

    Adjuvant paclitaxel–carboplatin a potential alternative for TNBC patients

    Phase 3 results from China suggest that paclitaxel plus carboplatin could be an adjuvant therapy option for patients with operable triple-negative breast cancer.

  5. 25-03-2020 | Non-small-cell lung cancer | News | Article

    Carboplatin–pemetrexed should be ‘a standard option’ for older NSCLC patients

    Carboplatin–pemetrexed plus pemetrexed maintenance is noninferior to docetaxel for the first-line treatment of advanced non-small-cell lung cancer in patients aged 75 years or older, suggests a phase 3 Japanese study.

  6. 20-09-2019 | Castration-resistant prostate cancer | News | Article

    Adding carboplatin to cabazitaxel benefits men with mCRPC

    Phase I/II research published in The Lancet Oncology shows that combining cabazitaxel with carboplatin has the potential to prolong progression-free survival in men with metastatic castration-resistant prostate cancer.

  7. 20-11-2017 | Cetuximab | Article

    Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study

    Herbst RS et al. Lancet Oncol 2017; 19(1): 101–114. doi:10.1016/S1470-2045(17)30694-0

  8. 20-04-2023 | Urothelial cancer | At a glance | Article

    At a glance: Second and later line immunotherapy for advanced urothelial carcinoma

    Post-hoc analysis in ESMO Open  in 2021 pointed to an atezolizumab OS benefit among SAUL participants who had previously received cisplatin or carboplatin, and identified prognostic markers for OS with second-line atezolizumab, including Bellmunt risk and PD-L1 expression.

  9. 10-10-2016 | Pembrolizumab | Article

    Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Langer CJ et al. Lancet Oncol 2016; 17(11): 1497–1508. doi: 10.1016/S1470-2045(16)30498-3

  10. 26-01-2023 | Non-small-cell lung cancer | News | Article

    Adding camrelizumab to chemo prolongs OS of patients with advanced nonsquamous NSCLC

    The team therefore believes that “the current analysis further [supports] the use of camrelizumab plus carboplatin and pemetrexed in [the] first-line treatment of advanced NSCLC without EGFR/ALK alterations.”

  11. 17-10-2022 | Testicular cancer | News | Article

    De-escalated chemoradiotherapy may be feasible strategy for stage II seminoma

    As described in The Lancet Oncology , 116 patients with treatment-naïve or relapsed seminoma were treated with one cycle of carboplatin to an area under the curve of 7.

  12. 16-01-2015 | Non-small-cell lung cancer | Article

    Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

    Bradley JD et al.  Lancet Oncol 2015; 16(2):187-99. doi:10.1016/S1470-2045(14)71207-0

  13. 14-10-2022 | Non-small-cell lung cancer | News | Article

    CHOICE-01 shows survival benefit of adding toripalimab to chemo in advanced NSCLC

    The CHOICE-01 trial enrolled 465 individuals with treatment-naïve locally advanced or metastatic NSCLC lacking EGFR or ALK alterations and randomly assigned them to receive intravenous toripalimab 240 mg or placebo every 3 weeks alongside four to six cycles of chemotherapy, consisting of nab-paclitaxel plus carboplatin for squamous disease and pemetrexed plus cisplatin or carboplatin for nonsquamous disease.

  14. 12-10-2022 | Small-cell lung cancer | News | Article

    First-line serplulimab plus chemo improves extensive-stage SCLC survival

    In the double-blind study conducted in China, Georgia, Poland, Russia, Turkey, and Ukraine, 585 patients who had not received prior systemic therapy for extensive-stage SCLC were randomly allocated to receive either intravenous serplulimab 4.5 mg/kg or placebo every 3 weeks until unacceptable toxicity, disease progression, or death, alongside up to four 3-weekly cycles of etoposide 100 mg/m 2 given on days 1–3 plus carboplatin AUC 5 on day 1.

  15. 28-09-2022 | Lung cancer | News | Article

    Incidental sinoatrial node irradiation may increase AF risk in lung cancer

    Chemotherapy was etoposide with cisplatin or carboplatin for four to six cycles among the patients with SCLC and weekly paclitaxel with carboplatin for up to six cycles among those with NSCLC, while RT was given at a total dose of 60–63 Gy in fractions of 1.8–2.1 Gy using 3-dimensional conformal RT or intensity-modulated RT techniques.

  16. 27-09-2022 | ESMO 2022 | Conference coverage | Article

    Real-world study corroborates maintenance avelumab advanced UC benefit

    Over half (57.6%) of the participants had received carboplatin plus gemcitabine chemotherapy, while 31.8% had received cisplatin plus gemcitabine, and 10.6% had received another regimen.

  17. 06-08-2021 | Urothelial cancer | Feature | Article
    Updated January 2023

    At a glance: First-line immunotherapy for advanced urothelial carcinoma

    IMvigor130 Phase 3 Patient population: Treatment-naïve patients with locally advanced or metastatic urothelial cancer Treatments: Atezolizumab 1200 mg on day 1 of each 21-day cycle alone or alongside gemcitabine plus carboplatin or cisplatin; or placebo plus chemotherapy https://clinicaltrials.gov/ct2/show/NCT02807636 Sponsor: Hoffmann-La Roche Initial results from this trial were published in The Lancet in 2020, and showed a significant improvement in the co-primary endpoint of progression-free survival (PFS) with the addition of atezolizumab rather than placebo to chemotherapy, at a median of 8.2 versus 6.3 months, and an 18% reduction in the risk for progression or death favoring the PD-L1 inhibitor.

  18. 10-09-2022 | ESMO 2022 | Conference coverage | Article

    No clinical benefit of adding oleclumab to durvalumab–chemo in advanced TNBC

    They recruited 127 women with inoperable locally advanced or metastatic TNBC and randomly assigned them to receive durvalumab 1500 mg every 4 weeks alongside weekly carboplatin AUC 1.5 plus paclitaxel 80 mg/m 2 either with or without oleclumab 3000 mg given every 2 weeks for five cycles and then every 4 weeks.

  19. 09-08-2022 | WCLC 2022 | Conference coverage | Article

    NADIM II: Adding nivolumab to neoadjuvant chemo improves stage III NSCLC survival

    Provencio reported that median PFS was unreached for the 57 patients with stage IIIA–B disease lacking EGFR and ALK alterations who were randomly assigned to receive three cycles of neoadjuvant nivolumab 360 mg alongside paclitaxel plus carboplatin, where all drugs were administered every 3 weeks.

  20. 06-06-2022 | ASCO 2022 | Conference coverage | Article

    SKYSCRAPER-02: Add-on tiragolumab ineffective in extensive-stage SCLC

    Adding tiragolumab to atezolizumab plus carboplatin and etoposide provides no additional progression-free or overall survival benefit to patients with untreated extensive-stage small-cell lung cancer, phase 3 study data show.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.